AstraZeneca holds talks with Bristol Myers Squibb on pharma megadeal

AstraZeneca is engaging in discussions with Bristol Myers Squibb concerning a pharmaceutical megadeal valued at $400 billion, according to reports from the FT. This strategic tie-up is intended to create one of the largest drugmakers in the world. The potential merger represents a significant consolidation within the industry, combining the resources and portfolios of both companies to establish a dominant global presence in the pharmaceutical sector through this massive financial agreement.